{"id":"placebo-for-pirfenidone","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. Any observed effects in placebo recipients are attributed to the placebo effect—psychological and physiological responses to the expectation of treatment rather than the drug itself. In this Phase 3 trial, placebo serves as the comparator arm to assess the true clinical benefit of pirfenidone.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:23.182Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 trial for idiopathic pulmonary fibrosis (pirfenidone comparison)"}]},"trialDetails":[{"nctId":"NCT06329401","phase":"PHASE2","title":"A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Avalyn Pharma Inc.","startDate":"2024-04-03","conditions":"Progressive Pulmonary Fibrosis","enrollment":375},{"nctId":"NCT05674994","phase":"PHASE3","title":"Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Fondation Hôpital Saint-Joseph","startDate":"2023-10-26","conditions":"Acute Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":110},{"nctId":"NCT05195918","phase":"PHASE1","title":"Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hal Chapman","startDate":"2023-08-24","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":50},{"nctId":"NCT05497284","phase":"PHASE2","title":"To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-11-10","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":46},{"nctId":"NCT07325357","phase":"PHASE4","title":"Effect of Pirfenidone on TA Fibrosis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-20","conditions":"Takayasu Arteritis","enrollment":92},{"nctId":"NCT06928272","phase":"PHASE3","title":"Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study","status":"RECRUITING","sponsor":"Douglas D. Fraser","startDate":"2025-09-10","conditions":"Long COVID","enrollment":348},{"nctId":"NCT05704166","phase":"PHASE2","title":"PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2023-03-16","conditions":"Acute Lung Injury, Prevention","enrollment":214},{"nctId":"NCT05350371","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of Pirfenidone in Acute Pancreatitis","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2023-08-01","conditions":"Pancreatitis, Acute","enrollment":60},{"nctId":"NCT06224790","phase":"PHASE4","title":"Perfenidone in Type 2 Diabetic Patients With Diabetic Neuropathy","status":"COMPLETED","sponsor":"Sidrah Lodhi","startDate":"2024-03-10","conditions":"Diabetic Nephropathies, Type 2 Diabetes","enrollment":60},{"nctId":"NCT05713292","phase":"PHASE3","title":"Pirfenidone in Adult Hospitalized Patients With COVID-19","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2022-12-01","conditions":"COVID-19 Pneumonia","enrollment":168},{"nctId":"NCT03287414","phase":"PHASE2","title":"Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-12-20","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":30},{"nctId":"NCT04243837","phase":"PHASE2","title":"LYT-100 in Patients With BCRL","status":"TERMINATED","sponsor":"PureTech","startDate":"2020-03-01","conditions":"Breast Cancer Related Lymphoedema, Lymphoedema","enrollment":50},{"nctId":"NCT06267794","phase":"PHASE2","title":"Prolonged Release Pirfenidone Versus Placebo in Compensated Cirrhosis.","status":"COMPLETED","sponsor":"Jorge L Poo","startDate":"2015-06-26","conditions":"Liver Fibrosis, Cirrhosis, Liver, Chronic Liver Disease","enrollment":180},{"nctId":"NCT04652518","phase":"PHASE2","title":"LYT-100 in Post-acute COVID-19 Respiratory Disease","status":"TERMINATED","sponsor":"PureTech","startDate":"2020-12-11","conditions":"Covid19, Post-acute COVID-19 Respiratory Disease","enrollment":185},{"nctId":"NCT03221257","phase":"PHASE2","title":"Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate","status":"COMPLETED","sponsor":"Michael Roth","startDate":"2017-11-28","conditions":"Scleroderma, Systemic, Interstitial Lung Disease","enrollment":51},{"nctId":"NCT05826821","phase":"","title":"Biomarkers in HF: Circulating Biomarkers of Fibrosis and Cardiovascular Disease","status":"COMPLETED","sponsor":"Manchester University NHS Foundation Trust","startDate":"2017-03-02","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":107},{"nctId":"NCT02689778","phase":"PHASE3","title":"Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic Nephropathy","status":"COMPLETED","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2016-03","conditions":"Diabetic Nephropathy, Albuminuria","enrollment":62},{"nctId":"NCT02958917","phase":"PHASE2","title":"Study of Efficacy and Safety of Pirfenidone in Patients With Fibrotic Hypersensitivity Pneumonitis","status":"TERMINATED","sponsor":"Evans Fernandez Perez","startDate":"2017-06-05","conditions":"Interstitial Lung Disease","enrollment":40},{"nctId":"NCT04419506","phase":"PHASE2","title":"A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-07-28","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":147},{"nctId":"NCT02808871","phase":"PHASE2","title":"Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2017-04-07","conditions":"Rheumatoid Arthritis Interstitial Lung Disease","enrollment":123},{"nctId":"NCT03733444","phase":"PHASE3","title":"A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care","status":"TERMINATED","sponsor":"Galapagos NV","startDate":"2018-11-05","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":781},{"nctId":"NCT03711162","phase":"PHASE3","title":"A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care","status":"TERMINATED","sponsor":"Galapagos NV","startDate":"2018-11-28","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":525},{"nctId":"NCT02871401","phase":"PHASE1","title":"A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2018-01-03","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":31},{"nctId":"NCT03725852","phase":"PHASE2","title":"A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)","status":"COMPLETED","sponsor":"Galapagos NV","startDate":"2018-09-27","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":68},{"nctId":"NCT02951429","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary Hypertension","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-12-31","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":177},{"nctId":"NCT01890265","phase":"PHASE2","title":"Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2013-07-30","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":160},{"nctId":"NCT02932566","phase":"PHASE2","title":"The Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction","status":"COMPLETED","sponsor":"Manchester University NHS Foundation Trust","startDate":"2017-03-02","conditions":"Cardiac Failure","enrollment":129},{"nctId":"NCT02262299","phase":"PHASE2, PHASE3","title":"European Trial of Pirfenidone in BOS, A European Multi-center Study","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2015-05","conditions":"Disorder Related to Lung Transplantation, CLAD, Bronchiolitis Obliterans","enrollment":90},{"nctId":"NCT03856853","phase":"PHASE3","title":"Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease","status":"UNKNOWN","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2018-06-15","conditions":"Systemic Sclerosis-associated Interstitial Lung Disease (Ssc-ild)","enrollment":144},{"nctId":"NCT01872689","phase":"PHASE2","title":"A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-10-13","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":505},{"nctId":"NCT00001596","phase":"PHASE2","title":"Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome","status":"COMPLETED","sponsor":"William Gahl, M.D.","startDate":"2005-09","conditions":"Albinism, Inborn Errors of Metabolism, Oculocutaneous Albinism","enrollment":35},{"nctId":"NCT03260556","phase":"PHASE4","title":"Pirfenidone for Progressive Fibrotic Sarcoidosis","status":"UNKNOWN","sponsor":"University of Cincinnati","startDate":"2017-09-27","conditions":"Sarcoidosis, Pulmonary","enrollment":60},{"nctId":"NCT00287716","phase":"PHASE3","title":"Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-07-14","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":435},{"nctId":"NCT00287729","phase":"PHASE3","title":"Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-04","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":344},{"nctId":"NCT03068234","phase":"PHASE2, PHASE3","title":"Pirfenidone as Treatment of Skin Fibrosis in Systemic Sclerosis","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2017-05","conditions":"Systemic Sclerosis","enrollment":72},{"nctId":"NCT02707640","phase":"PHASE2","title":"A Study to Assess the Safety and Tolerability of N-Acetylcysteine When Administered With Pirfenidone to Participants With Idiopathic Pulmonary Fibrosis (IPF)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-08","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":123},{"nctId":"NCT02530359","phase":"PHASE4","title":"Pirfenidone Effect on the Recovery of Renal Function in Septic Acute Kidney Injury","status":"UNKNOWN","sponsor":"Hospital Civil de Guadalajara","startDate":"2015-10","conditions":"Acute Kidney Injury, Sepsis","enrollment":90},{"nctId":"NCT02496182","phase":"PHASE2, PHASE3","title":"Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment","status":"UNKNOWN","sponsor":"Grupo Medifarma, S. A. de C. V.","startDate":"2015-07","conditions":"Alveolitis Extrinsic Allergic, Pulmonary Fibrosis","enrollment":60},{"nctId":"NCT01136174","phase":"PHASE2","title":"Safety and PK Study of BIBF 1120 in Japanese Patients With IPF","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-05","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":50},{"nctId":"NCT02161952","phase":"PHASE2","title":"Pirfenidone, an Antifibrotic and Antiinflammatory Drug","status":"COMPLETED","sponsor":"University of Guadalajara","startDate":"2005-05","conditions":"Fibrosis, Hepatitis C Chronic","enrollment":150},{"nctId":"NCT02136992","phase":"PHASE2","title":"Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2011-12","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":160},{"nctId":"NCT01504334","phase":"PHASE2","title":"Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF)","status":"UNKNOWN","sponsor":"Beijing Kawin Technology Share-Holding Co., Ltd.","startDate":"2012-01","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":80},{"nctId":"NCT00063583","phase":"PHASE1, PHASE2","title":"Pirfenidone: A New Drug to Treat Kidney Disease in Patients With Diabetes","status":"COMPLETED","sponsor":"Sharma, Kumar, M.D.","startDate":"2003-06","conditions":"Diabetes Mellitus, Diabetic Nephropathy","enrollment":77}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":191,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for pirfenidone","genericName":"Placebo for pirfenidone","companyName":"Douglas D. Fraser","companyId":"douglas-d-fraser","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in Phase 3 trial for idiopathic pulmonary fibrosis (pirfenidone comparison).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}